A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study-Reference-Cited by-同舟云学术

A phase II trial of high-dose chemotherapy (HDCT) supported by hematopoietic stem-cell transplantation (HSCT) in germ-cell tumors (GCTs) patients failing cisplatin-based chemotherapy: the Multicentric TAXIF II study

Published:2014-09 Issue:9 Volume:25 Page:1775-1782
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Selle F.,Wittnebel S.,Biron P.,Gravis G.,Roubaud G.,Bui B.N.,Delva R.,Bay J.O.,Fléchon A.,Geoffrois L.,Caty A.,Soares D.G.,de Revel T.,Fizazi K.,Gligorov J.,Micléa J.M.,Dubot C.,Provent S.,Temby I.,Gaulet M.,Horn E.,Brindel I.,Lotz J.P.

Funder

Assistance Publique—Hôpitaux de Paris

French Ministry of Health

Baxter Lab

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference42 articles.

1. . European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG);Schmoll;Ann Oncol,2004

2. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer;Beyer;Ann Oncol,2013

3. A phase II trial of TIP (paclitaxel, ifosfamide and cisplatin) given as second-line (post-BEP) salvage chemotherapy for patients with metastatic germ cell cancer: a medical research council trial;Mead;Br J Cancer,2005